Frequency of hemorrhage after tooth extraction in patients treated with a direct oral anticoagulant: A multicenter cross-sectional study

PLoS One. 2022 Apr 7;17(4):e0266011. doi: 10.1371/journal.pone.0266011. eCollection 2022.

Abstract

Objective: Few studies have compared the frequency of hemorrhages after tooth extraction between patients taking direct oral anticoagulants (DOACs) and those taking warfarin or no anticoagulants. Further, the effects of the timing of DOAC administration and tooth extraction on the frequency of post-extraction hemorrhage have not been demonstrated. Therefore, we compared the frequency of post-extraction hemorrhages in patients in these different conditions and examined the effects of the timing of DOAC administration and tooth extraction on the frequency.

Design: Prospective multicenter study.

Setting: Eighty-six Japanese hospitals.

Participants: In total, 182 teeth extracted from 145 individuals (119 teeth from adult males) receiving dabigatran and 88 teeth from individuals (62 teeth from adult males) receiving rivaroxaban were included.

Intervention: Tooth extraction was followed by a 7-day observational period between November 1, 2008 and December 31, 2015. Dabigatran was administered twice daily; rivaroxaban was administered once a day.

Primary outcome measure: Hemorrhage after tooth extraction.

Results: The frequency of hemorrhage after tooth extraction was 1.65%, 3.41%, and 3.63% in those treated with dabigatran, rivaroxaban, and warfarin, respectively, and 0.39% in those who did not receive anticoagulants. Hemorrhages after tooth extraction were significantly higher in the rivaroxaban group than in patients who did not receive anticoagulants (P = 0.008). These frequencies did not differ significantly in the dabigatran and rivaroxaban groups compared to the warfarin group (P = 0.221 and P = 1.000, respectively).

Conclusions: The frequency of hemorrhaging after tooth extraction appeared to be similar in patients receiving continuous dabigatran or rivaroxaban and in those receiving continuous warfarin.

Publication types

  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Adult
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / drug therapy
  • Cross-Sectional Studies
  • Dabigatran* / adverse effects
  • Hemorrhage / chemically induced
  • Hemorrhage / drug therapy
  • Humans
  • Male
  • Prospective Studies
  • Pyridones / therapeutic use
  • Rivaroxaban / adverse effects
  • Tooth Extraction / adverse effects
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Pyridones
  • Warfarin
  • Rivaroxaban
  • Dabigatran

Grants and funding

The authors received no specific funding for this work.